Sidley represented Takeda Pharmaceutical Company Limited in the formation of a global collaboration with Ovid Therapeutics Inc., a privately held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases. This collaboration will focus on the clinical development and commercialization of Takeda's investigational new drug TAK-935, a novel, potent and highly selective CH24H inhibitor, in rare pediatric epilepsies. TAK-935 has successfully completed Phase 1 clinical development under Takeda's leadership and will be moving into Phase 1b/2a clinical studies, in rare epileptic encephalopathies, where patients continue to suffer from significant unmet medical needs. The Sidley team was led by Jeffrey Rothstein and included Scott Williams and Rachelle Soderstrom. For additional information, please click here.
Sidley Austin LLP published this content on 18 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 January 2017 01:51:03 UTC.
Original documenthttp://www.sidley.com/en/news/sidley-takeda-ovid-therapeutics-inc
Public permalinkhttp://www.publicnow.com/view/8760B1140B41CE3AA8C714B1A38C00BE4DBD78BB
